0111 EQRx Series B
BioCentury & Getty Images


Diverse syndicate stands behind EQRx’s mission with $500M series B round

Jan 12, 2021 | 12:37 AM GMT

EQRx is planning to deliver on its promise to provide equivalent or better low-cost drugs ahead of schedule with a $500 million series B, with diverse investor interest reflecting a mission that has only gained support during the pandemic.

The series B round, which comes one year after the company’s launch at last year’s J.P. Morgan

Read the full 791 word article

How to gain access

Continue reading with a
two-week free trial.